- Home
- UNCY vs HNNA Comparison
UNCY vs HNNA Comparison
Compare UNCY & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- HNNA
- Stock Information
- Founded
- UNCY 2016
- HNNA 1989
- Country
- UNCY United States
- HNNA United States
- Employees
- UNCY N/A
- HNNA N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- HNNA Investment Managers
- Sector
- UNCY Health Care
- HNNA Finance
- Exchange
- UNCY Nasdaq
- HNNA Nasdaq
- Market Cap
- UNCY 91.0M
- HNNA 86.4M
- IPO Year
- UNCY 2021
- HNNA N/A
- Fundamental
- Price
- UNCY $6.34
- HNNA $11.00
- Analyst Decision
- UNCY Strong Buy
- HNNA
- Analyst Count
- UNCY 4
- HNNA 0
- Target Price
- UNCY $6.38
- HNNA N/A
- AVG Volume (30 Days)
- UNCY 867.0K
- HNNA 6.9K
- Earning Date
- UNCY 08-13-2025
- HNNA 08-07-2025
- Dividend Yield
- UNCY N/A
- HNNA 4.80%
- EPS Growth
- UNCY N/A
- HNNA 83.55
- EPS
- UNCY N/A
- HNNA 1.25
- Revenue
- UNCY N/A
- HNNA $35,546,000.00
- Revenue This Year
- UNCY N/A
- HNNA N/A
- Revenue Next Year
- UNCY $1,458.53
- HNNA N/A
- P/E Ratio
- UNCY N/A
- HNNA $9.16
- Revenue Growth
- UNCY N/A
- HNNA 41.94
- 52 Week Low
- UNCY $2.02
- HNNA $6.95
- 52 Week High
- UNCY $11.00
- HNNA $13.88
- Technical
- Relative Strength Index (RSI)
- UNCY 48.29
- HNNA 62.91
- Support Level
- UNCY $4.70
- HNNA $10.61
- Resistance Level
- UNCY $7.58
- HNNA $11.32
- Average True Range (ATR)
- UNCY 1.20
- HNNA 0.42
- MACD
- UNCY -0.07
- HNNA 0.03
- Stochastic Oscillator
- UNCY 26.03
- HNNA 94.74
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.